

# HEADLINE HIGHLIGHTS

**A wrap up** of what's been happening in the life sciences industry

## Immunovaccine to Conduct Clinical Study for RSV

Immunovaccine Inc. has received clearance from Health Canada to conduct a Phase I clinical study of its respiratory syncytial virus (RSV) vaccine in healthy adults. RSV is a potentially severe respiratory virus that predominantly affects the elderly and infants. The RSV vaccine is formulated in Immunovaccine's proprietary DepoVax™ adjuvanting platform and is initially being developed to protect the elderly population from infection. In preclinical studies, the DepoVax-based vaccine demonstrated the ability to protect animals against RSV. Immunovaccine plans to initiate the Phase I trial in the first half of 2015, with initial data expected later this year.



Research Edition, or its ability to consistently generate the same, valid results repeatedly.

## Health Outcomes Worldwide Partners with Think Research

Health Outcomes Worldwide (HOW) has signed an agreement with Think Research, Canada's foremost provider of clinical decision support tools. The partnership will see HOW's award-winning how2trak® software integrated as a third party application into Think Research Group's cloud-based platform EntryPoint, immediately making it accessible to the Group's network of 300 North American health care organizations. How2trak® is available as a mobile app on all iOS and Android mobile devices. In real time, the how2trak® mobile app analyzes complex data sets to empower nurses and physicians with more knowledge to help them improve patient care and dramatically reduce costs.



## Densitas Presents New Technology in Europe

Densitas' new research technology was profiled during scientific sessions at the European Congress of Radiology in Vienna, Austria in March. Densitas Research Edition assesses mammographic breast density using "for presentation" digital mammography images. The presentation focused specifically on the technology itself, study results using 1,823 images showed excellent agreement between Densitas Research Edition density measures and radiologists' visual assessment. This concept is also known as 'face validity'. The research also confirmed the internal reliability of Densitas

## MedMira Multiplo Tests Used for Program in Central Asia

MedMira Inc. has received payment for an initial order of its Multiplo rapid tests which will be used in a collaborative mobile health initiative in Uzbekistan. Donated by the Government of the Russian Federation and aligned with UNAIDS and World Health Organization (WHO) global health priorities, these innovative mobile clinics are mini hospitals on wheels that travel to the most remote areas of a country providing cutting edge medical services, which would



## TruLeaf Opens Bigger Facility

TruLeaf began operations in its new expanded facility within the Perennia Innovation Centre in Bible Hill in January. They also announced a partnership with a US-based pharmaceutical company for production of biomass for clinical trials. Since its founding, TruLeaf has been focusing almost exclusively on leafy green and herb production. However, the research capacity of the team and the potential of controlled environments attract attention from more than just the food sector.